Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N-9 efficacy study

This article was originally published in The Tan Sheet

Executive Summary

Risk of HIV-1 infection was "especially high" in women who used nonoxynol-9 more than 3.5 times per day due to "an increasing frequency of lesions" caused by the spermicide, researchers report in Sept. 28 Lancet. Lut Van Damme, MD, Institute of Tropical Medicine, Antwerp, Belgium, et al., found that at low-frequency use, N-9 had no effect on HIV-1 infection. Researchers randomized 892 sex workers in South Africa, Thailand, Benin and Ivory Coast to either 3.5% N-9 gel or placebo; investigators conclude the drug "no longer has a part to play in HIV-1 prevention"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel